Kenneth M Heym MD

Pediatric Hematology & Oncology•Fort Worth, TX

Physician

Join to View Full Profile

1500 Cooper StFort Worth, TX 76104
Phone+1 682-885-4007
Fax+1 682-885-3914

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2002 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1999 - 2002
Vanderbilt University School of MedicineClass of 1999

Certifications & Licensure

CA State Medical License 2005 - Present
TX State Medical License 2006 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility Start of enrollment: 2009 Sep 01
RECRUITING
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Start of enrollment: 2011 Dec 01
Terminated
Phase 1, Phase 2
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Start of enrollment: 2013 Aug 20
Completed
Phase 2
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2016 Jan 14
Terminated
Phase 2
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Start of enrollment: 2019 Feb 12
Active, not recruiting
Phase 1, Phase 2
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Start of enrollment: 2019 Jul 03
ACTIVE_NOT_RECRUITING
PHASE3
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Start of enrollment: 2017 Mar 29
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Roles: Principal Investigator, Contact
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2017 Jun 15
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2021 Nov 15
SUSPENDED
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeu...
Nirali N Shah, Eric S Schafer, Yueh-Yun Chi, Jemily Malvar, Kenneth M Heym
Pediatric Blood & Cancer. 2025-05-01
Diagnostic BRAFV600E blood predicts treatment failure and neurodegeneration and redefines paradigms of pediatric LCH.
Howard Lin, Akanksha Batajoo, Erin Peckham-Gregory, Daniel Zinn, Olive S Eckstein
Blood. 2025-04-01
Life-threatening Lymphatic Malformation With Somatic Activating NRAS Mutation Successfully Treated With Trametinib: A Case Study.
Lindsay Zumwalt, Haley Schluterman, Anish Ray, Kenneth Heym
Journal of Pediatric Hematology/oncology. 2025-03-01

Press Mentions

Hospital Patients March to Erase CancerAugust 31st, 2018